PMID- 35518784
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - LncRNA MBNL1-AS1 Represses Proliferation and Cancer Stem-Like Properties of 
      Breast Cancer through MBNL1-AS1/ZFP36/CENPA Axis.
PG  - 9999343
LID - 10.1155/2022/9999343 [doi]
LID - 9999343
AB  - BACKGROUND: Emerging studies have revealed long noncoding RNAs (lncRNAs) were key 
      regulators of cancer progression. In this research, the expression and roles of 
      MBNL1-AS1 were explored in breast cancer (BC). METHODS: In this study, the 
      MBNL1-AS1 expression in breast cancer tissue, as well as in cell line, was 
      studied by qRT-PCR assays. The effects of MBNL1-AS1 on proliferation and stemness 
      were evaluated by MTT assays, colony formation assays, orthotopic breast tumor 
      mice models, extreme limiting dilution analysis (ELDA), fluorescence in situ 
      hybridization (FISH), flow cytometry assays, and sphere formation assays. Flexmap 
      3D assays were performed to show that MBNL1-AS1 downregulated the centromere 
      protein A (CENPA) secretion in BC cells. Western blot, RNA pull-down assays, RNA 
      immunoprecipitation (RIP) assays, and FISH were conducted to detect the 
      mechanism. RESULTS: The results showed that the expression levels of MBNL1-AS1 
      were downregulated in breast cancer tissues and cell lines. In vitro and in vivo 
      studies demonstrated that overexpression of MBNL1-AS1 markedly inhibited BC cells 
      proliferation and stemness. RNA pull-down assay, RIP assay, western blot assay, 
      and qRT-PCR assay showed that MBNL1-AS1 downregulated CENPA mRNA via directly 
      interacting with Zinc Finger Protein 36 (ZFP36) and subsequently decreased the 
      stability of CENPA mRNA. Restoration assays also confirmed that MBNL1-AS1 
      suppressed the CENPA-mediated proliferation and stemness in breast cancer cells. 
      CONCLUSIONS: The new mechanism of how MBNL1-AS1 regulates BC phenotype is 
      elucidated, and the MBNL1-AS1/ZFP36/CENPA axis may be served as a therapeutic 
      target for BC patients.
CI  - Copyright (c) 2022 Yu Ding et al.
FAU - Ding, Yu
AU  - Ding Y
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Li, Yingjie
AU  - Li Y
AD  - Department of Pathology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Duan, Yunqiang
AU  - Duan Y
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Wang, Wan
AU  - Wang W
AD  - Department of Breast Surgery, China-Japan Union Hospital of Jilin University, 
      Changchun, China.
FAU - Zheng, Wei
AU  - Zheng W
AD  - Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Cheng, Weilun
AU  - Cheng W
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Qi, Yuan
AU  - Qi Y
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Feng, Jianyuan
AU  - Feng J
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Chen, Ziang
AU  - Chen Z
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Yu, Tianshui
AU  - Yu T
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Hu, Anbang
AU  - Hu A
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Wang, Ting
AU  - Wang T
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Li, Mingcui
AU  - Li M
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Zhang, Hanyu
AU  - Zhang H
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Li, Yanling
AU  - Li Y
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Ma, Fei
AU  - Ma F
AUID- ORCID: 0000-0002-7068-8846
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Guo, Baoliang
AU  - Guo B
AUID- ORCID: 0000-0002-4022-6739
AD  - Department of General Surgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
LA  - eng
PT  - Journal Article
DEP - 20220426
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC9064507
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/05/07 06:00
MHDA- 2022/05/07 06:01
PMCR- 2022/04/26
CRDT- 2022/05/06 06:00
PHST- 2021/10/19 00:00 [received]
PHST- 2022/03/12 00:00 [revised]
PHST- 2022/03/30 00:00 [accepted]
PHST- 2022/05/06 06:00 [entrez]
PHST- 2022/05/07 06:00 [pubmed]
PHST- 2022/05/07 06:01 [medline]
PHST- 2022/04/26 00:00 [pmc-release]
AID - 10.1155/2022/9999343 [doi]
PST - epublish
SO  - J Oncol. 2022 Apr 26;2022:9999343. doi: 10.1155/2022/9999343. eCollection 2022.